Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-02-19
2009-06-02
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S059000, C549S062000
Reexamination Certificate
active
07541381
ABSTRACT:
β-lactamases are the most widespread resistance mechanism to β-lactam antibiotics, such as penicillins and cephalosporins. In response to these enzymes, inhibitors have been introduced. Unfortunately, these inhibitors are also β-lactams, and resistance to them has developed rapidly. Consequently, the present invention provides a novel structure-based approach to inhibitors of these enzymes.
REFERENCES:
patent: 4006007 (1977-02-01), Bollinger et al.
patent: 4531139 (1985-07-01), Seitz
patent: 5571821 (1996-11-01), Chan et al.
patent: 5783705 (1998-07-01), Blok et al.
patent: 5939431 (1999-08-01), Solomon et al.
patent: 1155119 (1963-10-01), None
patent: WO-00/07997 (2000-02-01), None
patent: WO02/22137 (2002-03-01), None
Clare et al. European Journal of Medicinal Chemistry, 34(6), 463-474, 1999.
El-Maghraby et al. Egyptian journal of Pharmaceutical Sciences 24(1-4), 105-115, 1985.
El-Maghraby et al. Proceeding of Indian National Science Academy, Part A, 53(3), 431-40, 1987.
Babic et al., Drug Resistance Updates 9, 142-156, 2006.
Paterson et al., Clinical Microbiological reviews 18(40, 657-686, 2005.
Powers Rachael A.
Shoichet Brian K.
Balasubramanian Venkataraman
Northwestern University
Reinhart Boener Van Deuren s.c.
LandOfFree
Non-covalent inhibitors of AmpC β-lactamase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-covalent inhibitors of AmpC β-lactamase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-covalent inhibitors of AmpC β-lactamase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4108276